CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP issued a solicitation to Capricor Therapeutics investors regarding a class action lawsuit alleging securities fraud related to Deramiocel's BLA submission. The complaint claims the company made false statements about changing statistical analysis plans without FDA agreement, posing a significant risk of non-approval.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.